Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders

Annals of Neurology

Volumn 68, Issue 3, 2010, Pages 342-352

  Kang, Yeon Joo ^a   Digicaylioglu, Murat ^a,e   Russo, Rossella ^a   Kaul, Marcus ^a,b   Achim, Cristian L ^b,c   Fletcher, Lauren ^a,e   Masliah, Eliezer ^c,d   Lipton, Stuart A ^a,b,d  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOPROTEIN GP 120; PROTEIN KINASE B; SOMATOMEDIN C; TAU PROTEIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MORPHOLINE DERIVATIVE; NERVE PROTEIN; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASTROCYTOSIS; CELL DAMAGE; CELL LOSS; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PAIRED HELICAL FILAMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE; WESTERN BLOTTING; ADULT; ANIMAL; ANIMAL EMBRYO; BRAIN CORTEX; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GENETICS; GLIA; HIV INFECTIONS; IMMUNOPRECIPITATION; INTRANASAL DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; NERVE CELL; OLFACTORY BULB; PATHOLOGY; PHOSPHORYLATION; PROCEDURES;

ADMINISTRATION, INTRANASAL; ADULT; ANIMALS; APOPTOSIS; CELLS, CULTURED; CEREBRAL CORTEX; CHROMONES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; IMMUNOPRECIPITATION; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; MORPHOLINES; NERVE TISSUE PROTEINS; NEUROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; OLFACTORY BULB; PHOSPHORYLATION; RATS; TAU PROTEINS;

EID: 77956372424     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22070     Document Type: Article

References (50)

1. Kolson DL. Neuropathogenesis of central nervous system HIV-1 infection. Clin Lab Med 2002;22:703-717. (Pubitemid 35014996)
2. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol 2004;157:3-10.
3. Mocchetti I, Bachis A, Masliah E. Chemokine receptors and neurotrophic factors: potential therapy against aids dementia? J Neurosci Res 2008;86:243-255.
4. Gorantla S, Liu J, Sneller H, et al. Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis. J Immunol 2007;179: 4345-4356.
5. Potula R, Poluektova L, Knipe B, et al. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 2005;106:2382-2390. (Pubitemid 41510811)
6. Toggas SM, Masliah E, Rockenstein EM, et al. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994;367:188-193. (Pubitemid 24031702)
7. Garden GA, Budd SL, Tsai E, et al. Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 2002;22:4015-4024. (Pubitemid 37465710)
8. Schifitto G, Navia BA, Yiannoutsos CT, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 2007;21: 1877-1886. (Pubitemid 47329764)
9. Morishita E, Masuda S, Nagao M et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997;76:105-116. (Pubitemid 26407940)
10. Dore S, Kar S, Quirion R. Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. Trends Neurosci 1997;20:326-331.
11. Brooker GJ, Kalloniatis M, Russo VC, et al. Endogenous IGF-1 regulates the neuronal differentiation of adult stem cells. J Neurosci Res 2000;59:332-341. (Pubitemid 30107972)
12. Nitta A, Zheng WH, Quirion R. Insulin-like growth factor 1 prevents neuronal cell death induced by corticosterone through activation of the PI3k/Akt pathway. J Neurosci Res 2004;76: 98-103. (Pubitemid 38445567)
13. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005;6:484-494. (Pubitemid 40769173)
14. Digicaylioglu M, Kaul M, Fletcher L, et al. Erythropoietin protects cerebrocortical neurons from HIV-1/gp120-induced damage. Neuroreport 2004;15:761-763. (Pubitemid 38453453)
15. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641-647. (Pubitemid 32772276)
16. Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997;272:11671-11673. (Pubitemid 27202724)
17. Kermer P, Klocker N, Labes M, Bahr M. Insulin-like growth factor-I protects axotomized rat retinal ganglion cells from secondary death via PI3-K-dependent Akt phosphorylation and inhibition of caspase-3 In vivo. J Neurosci 2000;20:2-8.
18. Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 2004;117:5721-5729. (Pubitemid 40123939)
19. Ishihara T, Hong M, Zhang B, et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999;24:751-762.
20. Digicaylioglu M, Garden G, Timberlake S, et al. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci U S A 2004;101:9855-9860. (Pubitemid 38869326)
21. Kaul M, Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci U S A 1999;96:8212-8216. (Pubitemid 29328434)
22. Green DA, Masliah E, Vinters HV et al. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. Aids 2005;19:407-411. (Pubitemid 40446187)
23. Born J, Lange T, Kern W, et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5: 514-516. (Pubitemid 34568991)
24. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH Jr. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127:481-496. (Pubitemid 38950662)
25. Fletcher L, Kohli S, Sprague SM, et al. Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. J Neurosurg 2009;111:164-170.
26. Rockenstein E, Torrance M, Adame A, et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007;27:1981-1991. (Pubitemid 46310321)
27. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001;410:988-994. (Pubitemid 32335850)
28. Rosenzweig MQ, Bender CM, Lucke JP, et al. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004;27:185-190.
29. Miller SB, Moulton M, O'Shea M, Hammerman MR. Effects of IGF-I on renal function in end-stage chronic renal failure. Kidney Int 1994;46:201-207. (Pubitemid 24210452)
30. Stanley LC, Mrak RE, Woody RC, et al. Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease. J Neuropathol Exp Neurol 1994;53:231-238.
31. Dou H, Ellison B, Bradley J, et al. Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci 2005;25:8375-8385. (Pubitemid 41324724)
32. Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier. Endocrinology 1994;135:1753-1761. (Pubitemid 24363863)
33. Pardridge WM. Brain drug development and brain drug targeting. Pharm Res 2007;24:1729-1732.
34. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000;97:10526-10531.
35. Jabri N, Schalch DS, Schwartz SL, et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulinresistant type II diabetic patients. Diabetes 1994;43:369-374. (Pubitemid 24064242)
36. Holloway L, Butterfield G, Hintz RL, et al. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994;79:470-479. (Pubitemid 24256538)
37. Raine AE. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988;1:97-100.
38. Singbartl G. Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Investig 1994;72:S36-S43. (Pubitemid 24208378)
39. Fulga TA, Elson-Schwab I, Khurana V, et al. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol 2007;9:139-148. (Pubitemid 46420856)
40. Cruz JC, Tseng HC, Goldman JA et al. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003;40:471-483.
41. Wittman CW, Wszolek MF, Shulman JM et al. Taupathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001;293:711-714.
42. Petito CK, Roberts B. Evidence of apoptotic cell death in HIV encephalitis. Am J Pathol 1995;146:1121-1130.
43. Ehrenreich H, Aust C, Krampe H, et al. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 2004;19:195-206. (Pubitemid 39361181)
44. Liu XF, Fawcett JR, Thorne RG, et al. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 2001;187:91-97.
45. Yu YP, Xu QQ, Zhang Q, et al. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005;387:5-10. (Pubitemid 41138199)
46. Wyss-Coray T, Masliah E, Toggas SM, et al. Dysregulation of signal transduction pathways as a potential mechanism of nervous system alterations in HIV-1 gp120 transgenic mice and humans with HIV-1 encephalitis. J Clin Invest 1996;97: 789-798. (Pubitemid 26057098)
47. Kins S, Beyreuther K. Teasing out the tangles. Nat Med 2006; 12:764-765; discussion 765.
48. Billingsley ML, Kincaid RL. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 1997;323(pt 3):577-591.
49. Han P, Dou F, Li F, et al. Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation. J Neurosci 2005;25:11542-11552. (Pubitemid 43098447)
50. Pei JJ, Braak E, Braak H, et al. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 1999; 58:1010-1019. (Pubitemid 29441929)